Codeine is a popular opioid prodrug dependent on the activity of the specific cytochrome P450 enzyme 2D6 (CYP2D6). This enzyme catalyses the production of the potent analgesic metabolite morphine, but genetic studies have demonstrated that individuals from different ethnic groups exhibit considerable variability in the functional capacities of their expressed CYP2D6 enzymes, and pharmacological studies have shown many commonly prescribed drugs can reduce the action of CYP2D6 enzymes. These findings have significant clinical implications for the rational prescription of effective analgesia, especially in a multicultural country like Australia.
Codeine is one of the most widely used drugs in Australia, commonly combined with paracetamol (acetaminophen) or a non-steroidal antiinflammatory drug. In 1998, "codeine 30 mg with paracetamol" was the fifth most frequently prescribed formulation in Australia 1 . However, codeine is a prodrug and its in vivo conversion to the active metabolite morphine, is required for analgesic effect 2 . Codeine itself has a low affinity for µ-opioid receptors 3 and ligand binding studies have demonstrated that codeine [3] [4] [5] [6] and its metabolites norcodeine and codeine-6-glucuronide 6 exhibit a 200 to 2800 times weaker affinity at µ-opioid receptors than morphine.
Recent advances in the understanding of drug metabolism [7] [8] [9] [10] have revealed significant inter-ethnic variation and also inter-individual variation within racial groups, in the ability to metabolically activate codeine 11, 12 and other opioid prodrugs [13] [14] [15] [16] . These findings have significant implications for Australian anaesthetists, because during the last 50 years the Australian population has evolved from a predomi-nantly Anglo-Saxon and indigenous mix, to become one of the most ethnically diverse countries in the world. Population estimates for 1998 identified 23% of the Australian population as born overseas, with significant migration continuing from Europe and more recently the Balkans, the Middle-East and Asia 17 . Furthermore, the 1996 Australian census showed that 27% of persons born in Australia had at least one overseas-born parent (second generation Australians) and 2.1% Australians broadly identified their origin as Aboriginal or Torres Strait Islander (Table 1) 17 . Also, Australians have high usage of prescribed drugs and many of these (e.g., some antihypertensives and antidepressants) have the potential to significantly reduce conversion of codeine to morphine. Whilst most variations in codeine metabolism result in reduced efficacy, enhanced metabolism in some individuals can result in increased adverse effects. This article summarizes the data of most importance to anaesthetists.
Codeine and morphine are both natural products of the opium poppy, Papaver somniferum, with codeine making up about 0.5% of natural opium 12 . The first pure codeine isolates were prepared in 1833. Its analgesic potential was quickly recognized 18 and it was used to treat moderate to severe pain. When administered parenterally, it is over 13-times less potent than morphine, but its relatively high oral bioavailability renders it only 6.5 times less potent than morphine via the oral route 19, 20 . Oral codeine is almost completely absorbed (95%) and has an oral bioavailability of between 40 and 80% 12 . Oral codeine dose can be usefully increased to 180 mg, but above this dose there is an apparent ceiling effect due to increased side-effects 12 .
Early studies showed that codeine was mainly metabolized by glucuronidation 21 . Subsequently, the relatively minor, but crucial, metabolic pathways of O-demethylation to morphine (the active metabolite) and N-demethylation to norcodeine (an inactive metabolite), were unequivocally demonstrated 22 .
ACTIVATION OF CODEINE ANALGESIA IS PRIMARILY DEPENDENT ON CYP2D6 ACTIVITY
In the late 1980s it became apparent that the O-demethylation of codeine was catalyzed via the specific cytochrome P450 enzyme, CYP2D6 [23] [24] [25] . In most individuals approximately 10% of an administered codeine dose is metabolized to morphine via O-demethylation 20 . CYP2D6 is most active in the liver (4% of total CYP activity), but it is also expressed in the lung 26 and mucosa of the duodenum and jejunum 10 , and CYP2D6 mRNA has been detected in human brain tissue 27 . Recently it has been demonstrated that CYP3A4 catalyses the N-demethylation of codeine to the inactive metabolite norcodeine [28] [29] [30] ( Figure 1 ). CYP3A4 is the most highly expressed cytochrome P450 enzyme in the liver (30% of total CYP activity). It is also expressed in the mucosa of the small intestine and animal studies suggest probable activity in the central nervous system (CNS) 10, 31 .
Following codeine administration, CYP2D6 has the crucial role generating morphine. This morphine is further metabolized in vivo to the very potent metabolite, morphine 6-glucuronide (M6G) and the partially active metabolite, normorphine (NM) 24, 32, 33 .
In humans systemic M6G is about twice as potent as morphine 34 , but once the blood brain barrier is bypassed the difference is impressive, with animal studies indicating M6G is some 100 times more potent than morphine in the CNS 35 . In young adults the half-life of morphine is about two to three hours, while that of M6G is somewhat longer 20, 36 . Following chronic morphine (or codeine) administration, M6G levels typically exceed those of morphine and this, taken together with its superior potency, means M6G accounts for a significant proportion of morphine's analgesic action 34, [37] [38] [39] [40] . Indeed clinical studies have demonstrated that a single dose of codeine given postoperatively may provide little effective analgesia, even in patients known to have normal CYP2D6 activity 32, [41] [42] [43] . In contrast, multiple oral dosing of codeine allows systemic accumulation of morphine and M6G 44 .
In the CNS, local conversion of codeine to morphine may have a crucial role, especially since codeine is known to penetrate the blood-brain barrier more rapidly than morphine 45 . Until recently, hepatic CYP2D6 and to a lesser extent intestinal and lung 46 CYP2D6 activity were assumed to be the exclusive sources of morphine evolution from codeine. Total Australian population 1996 18,310.7 Figure 1 : The pathways of codeine metabolism. Following a dose of codeine, 4 to 12 % is excreted unchanged in the urine, the remainder is metabolized. Conversion to morphine and norcodeine each account for approximately 10% of total codeine metabolism, the majority is metabolized via glucuronidation (60-70%) then excreted in the urine 20, 101 . Of these metabolites only morphine and its derivative morphine-6-glucuronide (M6G) exhibit significant activity at opioid receptors 20 .
However studies in rat brain preparations have detected significant O-demethylation of codeine 47, 48 and CYP2D1 (the rat homologue of human CYP2D6) has been detected in rat brain 49 . Similarly, CYP2D6 mRNA has recently been detected in the human brain tissue. This suggests that local generation of morphine via CYP2D6-dependent codeine metabolism may also occur in the CNS of humans. Thus the diffusion of plasma morphine (evolved systemically from codeine) into the CNS may not be the only route via which codeine can mediate its central analgesic effects. Indeed if codeine were metabolized to morphine very close to its site of action in the CNS, then the morphine levels in the plasma and even the cerebrospinal fluid (CSF) would predict analgesic efficiency poorly. This intriguing hypothesis remains to be comprehensively tested, though studies utilizing quinidine (see below) have suggested a small but significant contribution of local CNS CYP2D6 activity to the antinociceptive effects of codeine 50 .
INTER-ETHNIC VARIATION IN CYP2D6
ACTIVITY Over 20 years ago it was noted that plasma morphine levels were exceedingly low in some individuals following codeine intake 51, 52 , and some single-dose clinical trials suggested that codeine was not always superior to placebo 32, [41] [42] [43] . Coincidentally, it was also recognized that about 5 to 10% of Caucasians failed to express a functional CYP2D6 and so could not produce morphine following codeine intake 10, 53 . These individuals were labeled "poor metabolizers" (PM), while individuals with normal CYP2D6 activity were labelled "extensive metabolizers" (EM). Initially, phenotyping was assigned using probe drugs, commonly the CYP2D6 substrates sparteine, debrisoquinine, metoprolol or dextromethorphan 12, 54 . After oral ingestion of a probe drug, a urinary metabolic ratio is calculated, being the ratio between the parent drug and the CYP2D6-dependent metabolite. The CYP2D6 activity-deficient PMs are classified as lying above the cut-off ratios of 20 for sparteine, 12.6 for debrisoquine, 10.5 for metoprolol and 0.3 for dextromethorphan 12, 54 . Recently genetic typing has allowed more accurate detection and classification of various mutations in the CYP2D6 alleles and very considerable variation has been identified between different ethnic groups ( Table 2) .
The potential for inter-individual variation in drug metabolism due to polymorphism of cytochrome P450 enzymes is now widely recognized. The genes encoding CYP2A6, CYP2C9, CYP2C19 and CYP2D6 are functionally polymorphic, and at least 40% of cytochrome P450-dependent drug metabolism is catalyzed via these enzymes. For CYP2D6 over 30 different defective alleles and about 55 gene variants have been identified 9 but genotyping for the five or six most common defective alleles allows prediction of the CYP2D6-PM phenotype with about 90-95% accuracy ( Table 2) 9 . However, recent data from a variety of ethnic groups, particularly those from African and South American populations, suggest that the potential exists for significant allelic and phenotypic variation in CYP2D6 enzymes 53, [55] [56] [57] [58] [59] [60] [61] .
Most allelic variations of CYP2D6 are loss of function mutations that produce a PM phenotype. The alleles CYP2D6*4, and the less important CYP2D6*3, are expressed in high levels in Caucasians and are predominantly responsible for the PM phenotype. Although PM alleles have been reported as recessive 54 , co-dominant inheritance is more likely [62] [63] [64] , but due to the effects of gene dosage the PM phenotype (debrisoquinone ratio >12.6) is essentially limited to homozygotes (for loss of function alleles), with heterozygotes exhibiting qualitatively poorer EM phenotype 62 . In some studies these heterozygotes have been characterized and labelled "intermediate metabolizers" (IM) 62, 63 , and they exhibit a debrisoquinone ratio of about 0.3-10, compared to 0.1 to 0.5 for homozygous EM individuals 62 .
PM phenotype individuals exhibit reduced clearance of a number of important drugs and also decreased activation of the CYP2D6-dependent analgesic prodrugs including codeine 11, 12 , ethylmorphine 13 , hydrocodone 14 , oxycodone 15 and tramadol 16 (see Tables 3 and 4 ). Consequently PM individuals would be expected to obtain little benefit from these commonly used analgesics in their standard dose range, and indeed clinical trials of some of these drugs confirm this hypothesis 16, 32, 65 . However, there is no data on hydrocodone or oxycodone in this regard.
Although Caucasian populations have the highest rate of the PM phenotype individuals (Caucasians 5 to 10% versus Asians=1%) 10 , EM phenotype Caucasians appear to exhibit quantitatively more CYP2D6 activity than EM phenotype Chinese and Africans 26, [66] [67] [68] [69] . For example the median MR values for debrisquinone metabolism in Caucasians, Egyptians, Orientals and most African populations are approximately, 0.6, 0.6, 1.0 and 0.8 to 1.5, respectively 70 . Indeed even between apparently closely related racial groups differences exist. For example when Chinese individuals were compared to Japanese and Koreans they were found to exhibit less CYP2D6-dependent metabolism of both metoprolol 71 and codeine 72 . The reduced CYP2D6 activity observed in Oriental and African races appears to be due to the high expression of the mutant alleles CYP2D6*10 and CYP2D6*17 respectively, these code for CYP2D6 enzymes with reduced activity 26 (see Table 2 ).
Recently, individuals in some Caucasian, Middle Eastern and African populations have been shown to express an "ultrarapid metabolizing" (URM) phenotype (MR <0.2 for debrisoquinine 26 ). Genetic duplication of the allele CYP2D6*2 produces the URM phenotype (e.g., CYP2D6*2xN), which can result in abnormally high levels of morphine being produced from codeine. Consequently, following normal therapeutic doses of codeine these individuals can rapidly present with morphine associated adverse effects 67 and severe abdominal pain has also been reported 73 83 . 2D6*5 and *16 are deletion mutations, these occur at a similar frequency in all the populations, and probably occurred before the evolutionary separation of Caucasians, Negroids and Mongoloids, over 150,000 years ago 70, 83, 102 . The latest updates of allelic and functional variations for all the cytochrome P450 enzymes can be found at the webpage: http://www.imm.ki.se/CYPalleles/ dosage of primary drugs otherwise rapidly inactivated by CYP2D6 78 . Very recently limited data have become available describing the CYP2D6 phenotypes and genotypes of the indigenous peoples of Australia, New Zealand and the South Pacific. Archaeological, linguistic and mitochondrial genetic evidence suggests that the Polynesian peoples of the South Pacific Islands originated predominantly from the Mongoloid, Lapita peoples of South-East Asia (with some contribution from Melanesian inter-breeding) [79] [80] [81] . The Polynesians began their great maritime colonization of the South Pacific some 3,000 to 4,000 years ago and reached New Zealand a mere 800 to 1000 years ago 81 . In contrast, the Australian Aboriginals and the Melanesians of New Guinea and the Torres Strait Islands have a much more ancient lineage, originating well over 40,000 years ago from the Australoid peoples who then inhabited the lands of South East Asia 81 . Indeed, a phenotypic study of CYP2D6 activity in South Pacific Polynesians (75 to 100% ethnically pure) revealed a very low incidence of the PM phenotype (0%), resembling that of Asians 82 .
Similarly an investigation of CYP2D6 genetics of an Aboriginal community in the far north of Western Australia 83 has revealed a very low incidence of the 2D6*4, the allele associated with the PM phenotype in Caucasians (1.5% in Aborigines, cf. 12 to 21% in Caucasians and 1% in Asians, see Table 2 ). The profile of CYP2D6 alleles in these Aborigines also differed significantly from that of Asians or Africans. The frequency of the low activity CYP2D6*10 (0.8%) and CYP2D6*17 (0.2%) alleles contrasts with the 51% and 34% frequencies observed in Asians and Africans respectively (Table 2) . Significantly, the proportion of all loss of function and impairment mutations of CYP2D6 was low in these Aborigines, while the proportion of the functional CYP2D6*1 allele (85%) was the highest observed in any racial group 83 . This is perhaps consistent with the Australoid ancestry of Aborigines or specific adaption to the unique metabolic challenges of Australian native foods. Further studies are necessary to determine if ethnically pure Aborigines throughout the Australian continent share the robust EM profile demonstrated in this initial study 83 .
These investigations suggest that the PM phenotype is very rare in Aborigines and Polynesians, thus it is anticipated that essentially all ethnically pure indigenous people will benefit from codeine analgesia. However, many indigenous Australasians also have significant Caucasian ancestry due to extensive interbreeding over the last two centuries. For example, in a New Zealand Maori population where 97% of the individuals were mixed Caucasian or Asian ancestry, a 5% incidence of the "Caucasian" PM phenotype for CYP2D6-dependent metabolism was found 84 .
INTER-INDIVIDUAL VARIATION IN CYP2D6 ACTIVITY
There is little evidence for gender differences in CYP2D6 or CYP3A4 activity, but males may have a slightly higher capacity to glucuronidate codeine 85 . Similarly, smoking induces only the glucuronidation of codeine 30, 85 . No drugs have been found which both potently and selectively induce CYP2D6 9 . For example, although rifampicin (rifampin) moderately induces O-demethylation (CYP2D6) in patients taking codeine, it more profoundly induces the N-demethylation pathway (CYP3A4) and this results in reduced plasma codeine and thus reduced morphine levels 86 . CYP2D6 activity of EM phenotype individuals appears to be conserved even in the setting of moderately severe liver disease 87 , and at least in Caucasian women, activity is largely independent of the hormonal phase of the menstrual cycle 88 . However, CYP2D6 activity does increase significantly during pregnancy 89 , suggesting routine dosage adjustment for drugs that are CYP2D6 substrates should be considered in pregnant women.
Well over 50 drugs have been identified as CYP2D6-dependent substrates and several others act as CYP2D6 inhibitors (Table 3) . Many commonly used drugs also inhibit CYP2D6 activity when used within their normal therapeutic range 10 . Some of the more potent CYP2D6 inhibitors include the selective serotonin uptake inhibitors (SSRIs; especially paroxetine and fluoxetine) 90 , methadone 91 , terbinafine 92 and quinidine 23 . Since codeine has a relatively low affinity for CYP2D6 (K m =100-200 µM) 23, 93 , its conversion to morphine and thus its analgesic efficiency is readily blocked by the more potent CYP2D6 inhibitors. The class Ia anti-arrythmic quinidine, itself a substrate of CYP3A4, acts as a very potent inhibitor of CYP2D6 (apparent K i =15 nM) 23 . It has commonly been used to block CYP2D6-dependent codeine metabolism in humans 50, 66, 78 , and it effectively generates an experimental "poor metabolizer" phenotype. Although quinidine penetrates the blood brain barrier poorly, quinidine pre-treatment leads to pronounced lowering of both blood and cerebrospinal fluid morphine concentrations in patients taking codeine 94 . As described above, the recent identification of CYP2D6 in the human CNS 27 suggests the possibility that local CNS production of morphine from codeine could occur without significant rises in the total CSF morphine concentration 12, 50 .
Drugs that inhibit of CYP2D6-dependent codeine metabolism (and other opioid prodrugs) are likely to have a significant effect on the analgesic potential of codeine. In vitro CYP2D6 inhibition assays may one day prove to be valuable clinical tools for the elucidation of possible drug interaction with opioid prodrug metabolism 93, 95 and thus avoid administration of codeine where it would not be effective.
Whilst it is reported that codeine has a direct antitussive action independent of its conversion to morphine 20 , other direct actions hypothesized for codeine are more controversial. Codeine has been proposed to directly cause adverse effects like increased gastrointestinal transit time and nausea and vomiting. Several small clinical trials comparing PM and EM individuals have produced contradictory findings. Following an oral codeine dose some investigators have detected adverse effects in both PM and EM individuals 96, 97 , while others have found significant adverse effect in only EM individuals 65, 98 . A more thorough investigation of the area is warranted before rational conclusions can be drawn, nevertheless following a dose of codeine it is possible that PM individuals will suffer both the absence of analgesia and adverse effects.
Interestingly, PM individuals are significantly under-represented in populations of opioid prodrugdependent individuals 99 . Consequently it has been hypothesized that PM phenotype confers protection against the establishment of oral opioid prodrug addiction, precisely because it blocks the formation of directly active opioids 99 . Indeed, codeine-dependent individuals have been successfully treated recently by utilizing the potent CYP2D6 inhibitor fluoxetine to produced a "pseudo-PM" phenotype in EM individuals ("phenocopying"), thus blocking morphine formation and dependence reward 100 .
CONCLUSION
In the last decade there has been increasing evidence that patients are pharmacologically unique. Each patient can potentially express a diverse range of receptor activities, metabolic functionality and adverse reactions to drugs. An appreciation and growing elucidation of the role of the cytochrome P450 enzyme family in the catabolism of active drugs and the activation of prodrugs may soon allow relatively accurate profiling of each patient's metabolic and pharmacological idiosyncrasies. The CYP2D6dependent prodrugs, including the very popular analgesic codeine, provide an excellent and pertinent example of the value of this approach. Until then, anaesthetists must be aware that many patients will not derive the desired pain relief from codeine. Thus the patient's ethnic background and concurrent drug therapy should be considered before prescribing codeine or other opioid prodrugs.
Considering that 5 to 10% of Caucasians lack fully functional CYP2D6, then 1/10 to 1/20 of these patients can be expected to receive little or no effective analgesia from codeine (c.f. ~1/100 Asians). In constrast, while the PM phenotype is rare in African, Polynesian and Asian patients, EM individuals from these ethnic groups tend to produce morphine from codeine much less effectively than EM Causasians. Thus they may receive slower onset and/or suboptimal analgesia from doses of codeine that are normally effective in Caucasians. Pharmacological interactions are also important regulators of CYP2D6 activity. Patients requiring analgesia are often taking other medications, some of which may metabolically compete with or directly inhibit CYP2D6 activity (Table 4 ). Co-administration of CYP2D6 enzyme inhibitors like some SSRIs, terbinifine, quinidine etc., effectively produces a "pseudo-PM" phenotype, thus rendering codeine and the other CYP2D6-dependent analgesic prodrugs therepeutically useless.
So should the clinical use of CYP2D6-dependent prodrugs like codeine, tramadol, hydrocodone, ethylmorphine and oxycodone be abandoned for all patients? Certainly, when patients reliably report the absence of effective analgesia in the presence of adequate doses of these opioid prodrugs, then they should receive directly active opioid analgesics such as morphine or pethidine. However, opioid prodrugs, including codeine, have favourable characteristics as analgesics, at least in EM patients. Codeine has a better oral bioavailability than morphine, and being a prodrug, it may provide extended local production of morphine near its site of action. Possibly, when longterm use of codeine and other opioid prodrugs for pain relief is being considered (for example in cancer patients), it could be preceded by genetic and/or phenotypic investigations to determine the CYP2D6-PM, -EM or -URM profile of that patient.
Codeine should remain in the active formulary of anaesthetists, but its mode of activation and how this can differ between patients must be understood for the well-being of patients requiring effective analgesia. If patients report codeine as ineffective or they have been prescribed drugs that affect CPY2D6 activity, analgesia not requiring CYP3D6 activation should be used.
